Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Eupraxia Pharmaceuticals has a consensus analyst rating of Moderate Buy from eight brokers (2 sell, 4 buy, 2 strong buy) with an average 12‑month price target of $15.00.
• The company reported an earnings miss—quarterly EPS of ($0.37) vs. estimates of ($0.16)—and the stock trades around $7.16 with a market cap of roughly $432.7M and a 12‑month range of $3.67–$9.32.
• Eupraxia is a clinical‑stage biotech focused on selectively expanding regulatory T cells (Tregs), with its lead therapeutic candidate currently in Phase 1 development for systemic lupus erythematosus.

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eight brokerages that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, four have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $15.00.

A number of equities analysts have weighed in on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Eupraxia Pharmaceuticals in a report on Tuesday. Zacks Research downgraded Eupraxia Pharmaceuticals from a "hold" rating to a "strong sell" rating in a report on Tuesday, March 17th. Cantor Fitzgerald increased their target price on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an "overweight" rating in a research report on Thursday, January 15th. HC Wainwright reiterated a "buy" rating and issued a $11.00 target price on shares of Eupraxia Pharmaceuticals in a report on Wednesday. Finally, William Blair started coverage on Eupraxia Pharmaceuticals in a research report on Monday, March 23rd. They set an "outperform" rating for the company.

Institutional Trading of Eupraxia Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Integrated Wealth Concepts LLC purchased a new position in Eupraxia Pharmaceuticals in the third quarter valued at approximately $71,000. Bank of America Corp DE grew its stake in Eupraxia Pharmaceuticals by 402.4% during the second quarter. Bank of America Corp DE now owns 12,559 shares of the company's stock worth $72,000 after buying an additional 10,059 shares during the period. Guardian Wealth Advisors LLC NC purchased a new stake in Eupraxia Pharmaceuticals during the fourth quarter worth approximately $76,000. Aptus Capital Advisors LLC acquired a new stake in shares of Eupraxia Pharmaceuticals in the fourth quarter worth $76,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Eupraxia Pharmaceuticals in the fourth quarter worth $105,000.

Eupraxia Pharmaceuticals Price Performance

NASDAQ EPRX opened at $7.16 on Friday. The company has a market cap of $432.68 million, a P/E ratio of -6.95 and a beta of 1.55. Eupraxia Pharmaceuticals has a 12 month low of $3.67 and a 12 month high of $9.32. The company has a 50-day moving average of $7.50 and a 200-day moving average of $7.14.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last released its earnings results on Thursday, March 19th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.21). As a group, equities research analysts anticipate that Eupraxia Pharmaceuticals will post -0.71 EPS for the current year.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc NASDAQ: EPRX is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company's core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.